ALS LIMITED (ALQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALQ - ALS LIMITED

Year End: March
GICS Industry Group : Commercial & Professional Services
Debt/EBITDA: 2.92
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ALS Ltd provides laboratory and testing services across the mining, industrial and life sciences sector. It operates in over 65 countries. Formerly Campbell Brothers Ltd it first listed in 1952 and changed name to ALS in 2012.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.66

21 Nov
2024

0.330

OPEN

$15.52

2.15%

HIGH

$15.66

1,903,895

LOW

$15.29

TARGET
$16.35 4.4% upside
Franking for last dividend paid out: 30%
OTHER COMPANIES IN THE SAME SECTOR
3DA . AVD . BSA . CG1 . CLG . CVL . CWY . CXL . DOW . DUR . EGN . EVS . FLC . IPG . LBL . MAD . PPK . RWL . SDV . SHA . SND . SSM . VEE . VNT .
FNARENA'S MARKET CONSENSUS FORECASTS
ALQ: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx 2.7 63.4 xxx
DPS (cps) xxx 39.2 38.0 xxx
EPS Growth xxx - 95.4% 100.0% xxx
DPS Growth xxx - 1.3% - 3.1% xxx
PE Ratio xxx N/A 25.5 xxx
Dividend Yield xxx N/A 2.3% xxx
Div Pay Ratio(%) xxx 1468.2% 59.9% xxx

Dividend yield today if purchased 3 years ago: 3.16%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.43

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 12/06 - ex-div 19.6c (franking 20%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx2.7
DPS All xxxxxxxxxxxxxxx39.2
Sales/Revenue xxxxxxxxxxxxxxx2,461.6 M
Book Value Per Share xxxxxxxxxxxxxxx244.4
Net Operating Cash Flow xxxxxxxxxxxxxxx359.2 M
Net Profit Margin xxxxxxxxxxxxxxx0.52 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.01 %
Return on Invested Capital xxxxxxxxxxxxxxx0.48 %
Return on Assets xxxxxxxxxxxxxxx0.36 %
Return on Equity xxxxxxxxxxxxxxx1.01 %
Return on Total Capital xxxxxxxxxxxxxxx15.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx17.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx318 M
Long Term Debt xxxxxxxxxxxxxxx1,554 M
Total Debt xxxxxxxxxxxxxxx1,872 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx300 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx151.7 M
Capex % of Sales xxxxxxxxxxxxxxx6.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,624 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx371 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx46 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

20/11/2024

1

Buy

$17.50

11.75%

ALS Ltd reported 1H25 net profit in line with the recent trading update, UBS observes.

Commodities reported around 6% growth, with underlying performance impacted by forex and weaker exploration activity.

Life sciences reported earnings growth of 21%, boosted by recent acquisitions, and Nuvisan returned to profitability, the analyst highlighted.

Management reiterated FY25 guidance. UBS maintains a Buy rating with a target price increase to $17.50 from $16.30.

The broker raises EPS forecasts by 1% for FY25 and FY26.

FORECAST
UBS forecasts a full year FY25 dividend of 38.00 cents and EPS of 63.00 cents.
UBS forecasts a full year FY26 dividend of 44.00 cents and EPS of 72.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Goldman Sachs

23/09/2024

1

Buy

$14.85

-5.17%

Goldman Sachs observes the 1H25 trading update from ALS Ltd with a -5% decline in expected net profit because of weaker commodities and higher financing costs, via leases and interest expenses.

Life sciences offset some of the weakness including over 10% growth in environmental across all geographies.

The broker cuts EBIT forecasts by -6% in FY25 and -4% in FY26.

Buy rating unchanged. Target price falls -5% to $14.85.

FORECAST
Goldman Sachs forecasts a full year FY25 dividend of 27.00 cents and EPS of 62.00 cents.
Goldman Sachs forecasts a full year FY26 dividend of 40.00 cents and EPS of 68.00 cents.

ALQ STOCK CHART